On the 13th, the State Council Information Office held a series of themed press conferences on promoting high-quality development. At the meeting, a reporter asked: the quality of drugs is directly related to public health and life safety. We have noticed that the National Medical Products Administration is implementing a drug safety consolidation and improvement action. May I ask, what is the current progress and effectiveness? How will the National Medical Products Administration further strengthen the supervision of drug quality and safety? Regarding this, Zhao Junning, Deputy Director of the National Medical Products Administration, stated that the National Medical Products Administration attaches great importance to drug safety, continues to purify the order of the drug market, and maintains a stable and positive drug safety situation. Starting from June 2023, the National Medical Products Administration will deploy a one-and-a-half-year drug safety consolidation and improvement action to comprehensively strengthen the bottom line of drug safety and resolutely safeguard the health rights and interests of the people. Firstly, focus on prominent issues and actively resolve risks and hidden dangers. Focusing on key products, key links, key regions, and key enterprises, we will conduct in-depth inspections on drug operation and use, special drugs, production commissioned by medical device registrants, clinical trial supervision and spot checks on medical devices, and special inspections on hair dye cosmetics. We will comprehensively investigate and resolve risks and hidden dangers through multiple channels and dimensions, fully leverage our risk warning, risk identification, and risk disposal capabilities, and take effective measures to timely resolve drug safety risks and hidden dangers. Secondly, we will rigorously investigate major and important cases, and crack down on illegal and criminal activities. Through the comprehensive use of typical case exposure, publication of serious illegal and dishonest lists, and other means, we will implement "punishment to individuals" for illegal behavior, implement joint punishment, industry bans, and employment bans, severely punish serious illegal and criminal activities, and effectively ensure the stability of drug safety situation. Thirdly, improve institutional mechanisms and comprehensively enhance regulatory capabilities. Promote the implementation of local management responsibilities, strengthen departmental regulatory responsibilities, tighten and compact the main responsibilities of enterprises, and form a strong joint force for drug safety management. The National Medical Products Administration and the State Administration for Market Regulation jointly issued the "Guiding Opinions on Strengthening Cross regional and Cross level Drug Supervision Coordination", which strengthens the supervision coordination of drug regulatory departments at the national, provincial, municipal, and county levels throughout the entire life cycle of drugs. Jointly issued the "Guidelines for Inspection and Identification of Suspected Criminal Cases in the Pharmaceutical Industry" with the Ministry of Public Security, and achieved practical results in promoting the connection of execution. Organize the identification of 142 city and county-level drug regulatory departments as grassroots contact points to achieve demonstration and leadership effects. The drug supervision and management departments in various regions actively develop the teams of township drug safety coordinators and rural drug safety information officers, promote the extension of drug supervision to grassroots areas such as townships and rural areas, and enhance the comprehensive governance efficiency at the grassroots level. Zhao Junning pointed out that in the next step, the National Medical Products Administration will continue to focus on the key tasks of consolidating and improving drug safety, continuously increase work efforts, concentrate on investigating and punishing a number of major cases, and severely punish illegal and irregular behaviors. Strengthen the investigation and resolution of risks and hidden dangers, and establish a solid bottom line for drug safety. (New Society)